Adults (≥ 18 Years)
Primary Hypercholesterolaemia,PHARMACOR EZETIMIBE administered alone, or with an HMG-CoA reductase inhibitor
(statin), is indicated as adjunctive therapy to diet in patients with primary (heterozygous
familial and non-familial) hypercholesterolaemia.,Homozygous Familial Hypercholesterolaemia (HoFH),PHARMACOR EZETIMIBE, administered with a statin, is indicated for patients with HoFH.
Patients may also receive adjunctive treatments (e.g., LDL apheresis).,Homozygous Sitosterolaemia (Phytosterolaemia),PHARMACOR EZETIMIBE is indicated for the reduction of elevated sitosterol and
campesterol levels in patients with homozygous familial sitosterolaemia.,Prevention of Cardiovascular Disease,PHARMACOR EZETIMIBE, is indicated for administration in combination with the
maximum tolerated dose of a statin with proven cardiovascular benefit in patients with
coronary heart disease (CHD) and a history of acute coronary syndrome (ACS) in need of
additional lowering of LDL-C in the expectation of a modest further reduction in the risk of
cardiovascular events following at least one year of therapy (see Section 5.1 Pharmacodynamic Properties, Clinical trials).,Children and Adolescents 10-17 Years
(pubertal status: boys Tanner Stage II and above and girls who are at least one year postmenarche),Heterozygous Familial Hypercholesterolaemia (HeFH),PHARMACOR EZETIMIBE co-administered with simvastatin (doses up to 40 mg) is
indicated as an adjunctive therapy to diet in adolescent patients (10-17 years old) with
heterozygous familial hypercholesterolaemia where use of a combination product is
appropriate:,? Patients not appropriately controlled with a statin or ezetimibe alone
? Patients already treated with a statin and ezetimibe,Homozygous Familial Hypercholesterolaemia (HoFH),PHARMACOR EZETIMIBE co-administered with simvastatin (doses up to 40 mg) is
indicated in adolescent patients (10-17 years old) with HoFH. Patients may also receive
adjunctive treatments (e.g. LDL apheresis)

Adults (≥ 18 Years)
Primary Hypercholesterolaemia,PHARMACOR EZETIMIBE administered alone, or with an HMG-CoA reductase inhibitor
(statin), is indicated as adjunctive therapy to diet in patients with primary (heterozygous
familial and non-familial) hypercholesterolaemia.,Homozygous Familial Hypercholesterolaemia (HoFH),PHARMACOR EZETIMIBE, administered with a statin, is indicated for patients with HoFH.
Patients may also receive adjunctive treatments (e.g., LDL apheresis).,Homozygous Sitosterolaemia (Phytosterolaemia),PHARMACOR EZETIMIBE is indicated for the reduction of elevated sitosterol and
campesterol levels in patients with homozygous familial sitosterolaemia.,Prevention of Cardiovascular Disease,PHARMACOR EZETIMIBE, is indicated for administration in combination with the
maximum tolerated dose of a statin with proven cardiovascular benefit in patients with
coronary heart disease (CHD) and a history of acute coronary syndrome (ACS) in need of
additional lowering of LDL-C in the expectation of a modest further reduction in the risk of
cardiovascular events following at least one year of therapy (see Section 5.1 Pharmacodynamic Properties, Clinical trials).,Children and Adolescents 10-17 Years
(pubertal status: boys Tanner Stage II and above and girls who are at least one year postmenarche),Heterozygous Familial Hypercholesterolaemia (HeFH),PHARMACOR EZETIMIBE co-administered with simvastatin (doses up to 40 mg) is
indicated as an adjunctive therapy to diet in adolescent patients (10-17 years old) with
heterozygous familial hypercholesterolaemia where use of a combination product is
appropriate:,? Patients not appropriately controlled with a statin or ezetimibe alone
? Patients already treated with a statin and ezetimibe,Homozygous Familial Hypercholesterolaemia (HoFH),PHARMACOR EZETIMIBE co-administered with simvastatin (doses up to 40 mg) is
indicated in adolescent patients (10-17 years old) with HoFH. Patients may also receive
adjunctive treatments (e.g. LDL apheresis)

Adults (≥ 18 Years)
Primary Hypercholesterolaemia,PHARMACOR EZETIMIBE administered alone, or with an HMG-CoA reductase inhibitor
(statin), is indicated as adjunctive therapy to diet in patients with primary (heterozygous
familial and non-familial) hypercholesterolaemia.,Homozygous Familial Hypercholesterolaemia (HoFH),PHARMACOR EZETIMIBE, administered with a statin, is indicated for patients with HoFH.
Patients may also receive adjunctive treatments (e.g., LDL apheresis).,Homozygous Sitosterolaemia (Phytosterolaemia),PHARMACOR EZETIMIBE is indicated for the reduction of elevated sitosterol and
campesterol levels in patients with homozygous familial sitosterolaemia.,Prevention of Cardiovascular Disease,PHARMACOR EZETIMIBE, is indicated for administration in combination with the
maximum tolerated dose of a statin with proven cardiovascular benefit in patients with
coronary heart disease (CHD) and a history of acute coronary syndrome (ACS) in need of
additional lowering of LDL-C in the expectation of a modest further reduction in the risk of
cardiovascular events following at least one year of therapy (see Section 5.1 Pharmacodynamic Properties, Clinical trials).,Children and Adolescents 10-17 Years
(pubertal status: boys Tanner Stage II and above and girls who are at least one year postmenarche),Heterozygous Familial Hypercholesterolaemia (HeFH),PHARMACOR EZETIMIBE co-administered with simvastatin (doses up to 40 mg) is
indicated as an adjunctive therapy to diet in adolescent patients (10-17 years old) with
heterozygous familial hypercholesterolaemia where use of a combination product is
appropriate:,? Patients not appropriately controlled with a statin or ezetimibe alone
? Patients already treated with a statin and ezetimibe,Homozygous Familial Hypercholesterolaemia (HoFH),PHARMACOR EZETIMIBE co-administered with simvastatin (doses up to 40 mg) is
indicated in adolescent patients (10-17 years old) with HoFH. Patients may also receive
adjunctive treatments (e.g. LDL apheresis)

Adults (≥ 18 Years)
Primary Hypercholesterolaemia,PHARMACOR EZETIMIBE administered alone, or with an HMG-CoA reductase inhibitor
(statin), is indicated as adjunctive therapy to diet in patients with primary (heterozygous
familial and non-familial) hypercholesterolaemia.,Homozygous Familial Hypercholesterolaemia (HoFH),PHARMACOR EZETIMIBE, administered with a statin, is indicated for patients with HoFH.
Patients may also receive adjunctive treatments (e.g., LDL apheresis).,Homozygous Sitosterolaemia (Phytosterolaemia),PHARMACOR EZETIMIBE is indicated for the reduction of elevated sitosterol and
campesterol levels in patients with homozygous familial sitosterolaemia.,Prevention of Cardiovascular Disease,PHARMACOR EZETIMIBE, is indicated for administration in combination with the
maximum tolerated dose of a statin with proven cardiovascular benefit in patients with
coronary heart disease (CHD) and a history of acute coronary syndrome (ACS) in need of
additional lowering of LDL-C in the expectation of a modest further reduction in the risk of
cardiovascular events following at least one year of therapy (see Section 5.1 Pharmacodynamic Properties, Clinical trials).,Children and Adolescents 10-17 Years
(pubertal status: boys Tanner Stage II and above and girls who are at least one year postmenarche),Heterozygous Familial Hypercholesterolaemia (HeFH),PHARMACOR EZETIMIBE co-administered with simvastatin (doses up to 40 mg) is
indicated as an adjunctive therapy to diet in adolescent patients (10-17 years old) with
heterozygous familial hypercholesterolaemia where use of a combination product is
appropriate:,? Patients not appropriately controlled with a statin or ezetimibe alone
? Patients already treated with a statin and ezetimibe,Homozygous Familial Hypercholesterolaemia (HoFH),PHARMACOR EZETIMIBE co-administered with simvastatin (doses up to 40 mg) is
indicated in adolescent patients (10-17 years old) with HoFH. Patients may also receive
adjunctive treatments (e.g. LDL apheresis)